Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail shows promise for tough lung cancer

NCT ID NCT04526691

Ongoing Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a combination of two drugs—datopotamab deruxtecan (Dato-DXd) and pembrolizumab (Keytruda)—with or without standard chemotherapy in people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 145 participants are enrolled, and researchers are monitoring side effects and how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (Keytruda) with or without platinum chemotherapy

What this could lead to

If successful, this combination could offer a new treatment option for advanced lung cancer that may shrink tumors or slow disease progression.

What could go wrong

This is an early Phase 1b trial with only 145 participants, so results are preliminary. Side effects from the drug combination could be significant, and the approach may not prove effective in larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC NSCLC

Contacts and locations

Locations

  • (CIOCC-START) Hospital Universitario HM Sanchinarro

    Madrid, 28050, Spain

  • Azienda Ospedaliera San Gerardo

    Monza, 20052, Italy

  • Chung Shan Medical University Hospital

    Taichung, 40201, Taiwan

  • City of Hope

    Duarte, California, 91010, United States

  • H. Vall Hebrón (Vall Hebron Institut de Oncologia - VHIO)

    Barcelona, 08035, Spain

  • Hospital Puerta de Hierro

    Majadahonda, 28222, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Instituto Europeo Di Oncologica

    Milan, 20141, Italy

  • Istituto Nazionale Tumori Fondazione G. Pascale di Napoli Struttura di Oncologia

    Naples, 80131, Italy

  • Johns Hopkins Kimmel Cancer Center

    Washington D.C., District of Columbia, 20016, United States

  • Johns Hopkins Kimmel Cancer Center at Bayview

    Baltimore, Maryland, 21224, United States

  • Mayo Clinic

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • NEXT Oncology

    San Antonio, Texas, 78229, United States

  • National Cancer Center Hospital

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital NCKUH

    Tainan, 704, Taiwan

  • National Taiwan University Hospital NTUH

    Taipei, 100, Taiwan

  • Quantum Santa Fe

    Santa Fe, New Mexico, 87505, United States

  • START Madrid - Hospital Universitario Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • Showa Medical University Hospital

    Tokyo, 142-8555, Japan

  • Taichung Veterans General Hospital

    Taichung, 40705, Taiwan

  • The Skip Viragh Outpatient Cancer Building

    Baltimore, Maryland, 21287, United States